CSIMarket


Regen Biopharma Inc  (RGBP)
Other Ticker:  
 

Regen Biopharma Inc

RGBP's Fundamental analysis








Regen Biopharma Inc's sales fell by 0 % in I. Quarter 2023 from the same quarter a year ago. Ranking at No. 46

Major Pharmaceutical Preparations industry recorded deterioration of revenues by

Regen Biopharma Inc faced net loss in contrast to the net income a year ago in I. Quarter 2023

More on RGBP's Growth


Regen Biopharma Inc
realized net loss in trailing twelve months.

Company
PE TTM   
Industry
283.75
PE TTM    
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.8.


More on RGBP's Valuation
 
 Total Debt (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 42,187
 Net Income/Employee (TTM) $ -
 Receivable Turnover (TTM) 3.42
 Tangible Book Value (Per Share $)

Regen Biopharma Inc
realized net loss in trailing twelve months.

Company
PE TTM   
Industry
283.75
PE TTM    
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.8.